Trimbake Diptee, Singh Dharmendra, K Yogesh Gurav, Babar Prasad, S Varsha Dange, Tripathy Anuradha S
Department of Dengue and Chikungunya, Indian Council of Medical Research-National Institute of Virology, 20-A, Dr Ambedkar Road, Pune 411001, India.
Department of Medicine, Pimpri Chinchwad Municipal Corporation, Pimpri, Pune 411018, Maharashtra, India.
J Immunol Res. 2025 Feb 10;2025:9743866. doi: 10.1155/jimr/9743866. eCollection 2025.
Research on long-term follow-up in individuals who have recovered from coronavirus disease-19 (COVID-19) would yield insights regarding their immunity status and identify those who need booster vaccinations. This study evaluated the longevity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific cellular and humoral memory responses, as well as T cell effector functionalities, at 1-2 months ( = 40), 8-9 months ( = 40), and 12 months/1 year ( = 27) following recovery from SARS-CoV-2 infection. CTL response by enzyme-linked immunospot (ELISPOT); levels of cytokine by Bio-Plex, natural killer (NK), CD4+ helper, and CD8+ cytotoxic T cell functionalities using flow cytometry; anti-SARS-CoV-2 IgG by ELISA; and levels of neutralizing antibodies (NAbs) by surrogate virus NAb assay were assessed. The levels of SARS-CoV-2-specific IgG and NAb at 1-2 and 8-9 months postrecovery were hand in hand and appeared declining. SARS-CoV-2-specific B, memory B and plasma cells, and T cells sustained up to 8-9 months. Increased expression of CD107a/IFN-γ by NK cells and cytotoxic T cells at 8-9 months could be indicative of SARS-CoV-2-specific effector functions. Recovered individuals with positive and negative IgG antibody status displayed T cell response up to 1 year and 8-9 months, respectively, emphasizing the durabilty of effector immunity up to 8-9 months regardless of IgG antibody status. Overall, the recovered individuals exhibited robust immunological memory, sustained T cell response with effector functionality against SARS-CoV-2 that persists for at least 8-9 months.
对已从冠状病毒病-19(COVID-19)康复的个体进行长期随访研究,将有助于深入了解他们的免疫状态,并确定那些需要加强接种疫苗的人。本研究评估了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)特异性细胞和体液记忆反应的持久性,以及在从SARS-CoV-2感染康复后的1-2个月(n = 40)、8-9个月(n = 40)和12个月/1年(n = 27)时的T细胞效应功能。通过酶联免疫斑点法(ELISPOT)检测细胞毒性T淋巴细胞(CTL)反应;使用流式细胞术通过Bio-Plex检测细胞因子水平、自然杀伤(NK)细胞、CD4 +辅助性T细胞和CD8 +细胞毒性T细胞功能;通过酶联免疫吸附测定(ELISA)检测抗SARS-CoV-2 IgG;并通过替代病毒中和抗体(NAb)测定评估中和抗体(NAb)水平。康复后1-2个月和8-9个月时,SARS-CoV-2特异性IgG和NAb水平密切相关且呈下降趋势。SARS-CoV-2特异性B细胞、记忆B细胞和浆细胞以及T细胞可持续存在长达8-9个月。NK细胞和细胞毒性T细胞在8-9个月时CD107a/IFN-γ表达增加可能表明存在SARS-CoV-特异性效应功能。IgG抗体状态为阳性和阴性的康复个体分别在长达1年和8-9个月时表现出T细胞反应,强调了效应免疫在长达8-9个月内的持久性,与IgG抗体状态无关。总体而言,康复个体表现出强大的免疫记忆,针对SARS-CoV-2的具有效应功能的T细胞反应持续至少8-9个月。